Substance / Medication

Nonacog alfa

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Hemophilia A

Factor VII deficiency

Hemophilia B

Factor IX deficiency

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:

Nonacog alfa: an analysis of safety data from six prospective clinical studies in different patient populations with haemophilia B treated with different therapeutic modalities.

Rendo Pablo, Smith Lynne, Lee Hsiao-Yu et al. · Blood Coagul Fibrinolysis · 2015

PMID: 26196195Meta-Analysis

Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients.

Collins P W, Quon D V K, Makris M et al. · Haemophilia · 2018

PMID: 28833808RCT

Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B.

Mahlangu Johnny, Levy Howard, Lee Martin et al. · Haemophilia · 2021

PMID: 33960073TrialFull text (PMC)

Safety, pharmacokinetics, and pharmacodynamics of a next-generation subcutaneously administered coagulation factor IX variant, dalcinonacog alfa, in previously treated hemophilia B patients.

You Chur Woo, Hong Seung-Beom, Kim Suyeong et al. · J Thromb Haemost · 2021

PMID: 33540485Trial

Once-weekly prophylaxis regimen of nonacog alfa in patients with hemophilia B: an analysis of timing of bleeding event onset.

Tortella Bartholomew J, Carr Marcus E, Rendo Pablo et al. · Blood Coagul Fibrinolysis · 2021

PMID: 33631774Trial

Confirmation of longer FIX activity half-life with prolonged sample collection after single doses of nonacog alfa in patients with haemophilia B.

Hua Baolai, Wu Runhui, Sun FeiFei et al. · Thromb Haemost · 2017

PMID: 28331929Trial

A national French noninterventional study to assess the long-term safety and efficacy of reformulated nonacog alfa.

Lambert Thierry, Rothschild Chantal, Volot Fabienne et al. · Transfusion · 2017

PMID: 28337764Trial

Eftrenonacog Alfa: A Review in Haemophilia B.

Hoy Sheridan M · Drugs · 2017

PMID: 28646426Trial

Once-weekly prophylactic treatment vs. on-demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B.

Kavakli K, Smith L, Kuliczkowski K et al. · Haemophilia · 2016

PMID: 26823276Trial

Evaluation of the safety and efficacy of recombinant factor IX (nonacog alfa) in minimally treated and previously treated Chinese patients with haemophilia B.

Yang R, Zhao Y, Wang X et al. · Haemophilia · 2012

PMID: 22776196Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Nonacog alfa (substance)
SNOMED CT: 425189006
UMLS CUI: C2826076

Clinical Data

This intervention maps to 4 entities in the Ltrl knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.